Answers are grounded in this paper and cite their sources.
In the phase 2 FORTE trial, transplant-eligible newly diagnosed multiple myeloma patients aged ≤65 years were randomized to (R1) carfilzomib-lenalidomide-dexamethasone followed by autologous stem cell transplantation (KRd-ASCT), twelve cycles of KRd (KRd12), or carfilzomib-cyclophosphamide-dexamethasone followed by ASCT (KCd-ASCT). Eligible patients were then randomized (R2) to maintenance with carfilzomib for 2 years plus lenalidomide until progression (KR) or lenalidomide alone until progression (R). With extended follow-up (median 99 months from R1 and 85 months from R2), KRd-ASCT significantly increased progression-free survival (PFS, median 98 months) versus KRd12 (median 70 months; HR 0.71, p=0.027) and KCd-ASCT (median 67 months; HR 0.66, p=0.006). A significant benefit in PFS2 was also observed versus both KRd12 (HR 0.65, p=0.02) and KCd-ASCT (HR 0.68, p=0.04) and in terms of overall survival (OS) versus KCd-ASCT (8-year OS: 76% vs 68%; HR 0.65, p=0.04). KR maintenance significantly improved PFS versus R (HR 0.67, p=0.02), with a time-dependent effect persisting up to two years after carfilzomib discontinuation; no differences in PFS2/OS were observed. KR significantly increased rate of measurable residual disease (MRD) conversion (sHR 0.47, p=0.03) during active treatment, and reduced MRD resurgence (sHR 0.53, p=0.001) versus R. Median duration of MRD negativity was 50.5 months in KR vs. 38 months in R arm. MRD-negative patients had significantly prolonged PFS with KR (HR 0.60, p=0.031); MRD-positive patients benefited from KR mainly during carfilzomib therapy (HR 0.46, p=0.05). The cumulative incidence of second primary malignancies was 6%. In conclusion, long-term follow-up confirms the high effectiveness of KRd-ASCT and KR maintenance. NCT02203643
No takes yet. Share an insight, caveat, or question.
Bertuglia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: